Tempus AI Targets $20B MRD Market with $1.5B Personalis Acquisition
TEM sits 21% above its 52-week low of $41.73.
Summary
Tempus AI agreed to acquire Personalis for $1.5 billion in stock, integrating its leading MRD test into Tempus' AI-enabled precision oncology platform and targeting a $20 billion market.
Key Events · M&A and Partnerships · TEM
-
Acquisition of Personalis
Tempus AI will acquire all outstanding shares of Personalis not already owned for $16.25 per share, representing a total enterprise value of $1.5 billion net of its existing stake.
-
Deal Structure
Consideration is 100% stock with a floating exchange ratio capped at 0.3356 Tempus shares per Personalis share; Tempus may elect to pay up to 50% in cash.
-
Strategic Rationale
The acquisition integrates Personalis' ultrasensitive MRD test into Tempus' AI platform, expanding its reach across the cancer care continuum and targeting a $20 billion market opportunity.
-
Personalis Momentum
Personalis reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests, a 33% increase in test volumes quarter-over-quarter.
Analysis · TEM · Technology
In a thesis-altering move, Tempus AI is acquiring Personalis in an all-stock deal valued at $1.5 billion net of its existing stake, paying $16.25 per share — a 6% premium to the last close. The transaction brings Personalis' industry-leading minimal residual disease (MRD) test under Tempus' commercial umbrella, unlocking a $20 billion market opportunity. Structured with a floating exchange ratio capped at 0.3356 Tempus shares per Personalis share, the deal gives Tempus the option to pay up to 50% in cash. Underscoring the asset's momentum, Personalis delivered preliminary Q2 revenue of $22.4 million and a 33% sequential jump in test volumes. Closing is expected in late 2026 or early 2027, pending shareholder and regulatory approvals. This acquisition significantly expands Tempus' oncology platform and creates a new growth vector in cancer monitoring.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TEM was trading at $50.36 on NASDAQ in the Technology sector, with a market capitalization of approximately $9.4B. The 52-week trading range was $41.73 to $104.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.